Last reviewed · How we verify
GP combined with Tislelizumab
GP combined with Tislelizumab uses a chemotherapy backbone (likely gemcitabine/cisplatin) paired with an anti-PD-1 immunotherapy to kill cancer cells and enhance immune-mediated tumor destruction.
GP combined with Tislelizumab uses a chemotherapy backbone (likely gemcitabine/cisplatin) paired with an anti-PD-1 immunotherapy to kill cancer cells and enhance immune-mediated tumor destruction. Used for Advanced or metastatic solid tumors (specific indication under investigation in Phase 3 trial).
At a glance
| Generic name | GP combined with Tislelizumab |
|---|---|
| Sponsor | XIANG YANQUN |
| Drug class | PD-1 inhibitor combined with chemotherapy |
| Target | PD-1 (programmed death receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tislelizumab is a humanized PD-1 inhibitor that blocks the programmed death-1 checkpoint, releasing T-cell inhibition and promoting anti-tumor immunity. The GP chemotherapy regimen (gemcitabine and cisplatin) provides direct cytotoxic activity against cancer cells. The combination leverages chemotherapy's immunogenic cell death to synergize with checkpoint inhibition for enhanced therapeutic effect.
Approved indications
- Advanced or metastatic solid tumors (specific indication under investigation in Phase 3 trial)
Common side effects
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Chemotherapy-related myelosuppression
- Fatigue
- Nausea and vomiting
- Infusion reactions
Key clinical trials
- Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma (PHASE3)
- Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial (NA)
- Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC (PHASE3)
- Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC (PHASE2)
- Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma (PHASE2)
- Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma (PHASE2)
- VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS (PHASE2)
- Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP combined with Tislelizumab CI brief — competitive landscape report
- GP combined with Tislelizumab updates RSS · CI watch RSS
- XIANG YANQUN portfolio CI